FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2601907443> ?p ?o ?g. }

• W2601907443 endingPage "75880" @default.
• W2601907443 startingPage "75874" @default.
• W2601907443 abstract "// Kentaro Igarashi 1, 2, 3 , Kei Kawaguchi 1, 2 , Tasuku Kiyuna 1, 2 , Takashi Murakami 1, 2 , Shinji Miwa 3 , Scott D. Nelson 4 , Sarah M. Dry 4 , Yunfeng Li 4 , Arun S. Singh 5 , Hiroaki Kimura 3 , Katsuhiro Hayashi 3 , Norio Yamamoto 3 , Hiroyuki Tsuchiya 3 , Fritz C. Eilber 6 and Robert M. Hoffman 1, 2 1 AntiCancer, Inc., San Diego, CA, USA 2 Department of Surgery, University of California, San Diego, CA, USA 3 Department of Orthopedic Surgery, Kanazawa University, Kanazawa, Japan 4 Department of Pathology, University of California, Los Angeles, CA, USA 5 Division of Hematology-Oncology, University of California, Los Angeles, CA, USA 6 Division of Surgical Oncology, University of California, Los Angeles, CA, USA Correspondence to: Robert M. Hoffman, email: all@anticancer.com Fritz C. Eilber, email: fceilber@mednet.ucla.edu Keywords: rhabdomosarcoma, nude mice, patient-derived orthotopic xenograft (PDOX), temozolomide, irinotecan, combination Received: January 20, 2017     Accepted: February 27, 2017     Published: March 24, 2017 ABSTRACT Adult pleomorphic rhabdomyosarcoma (RMS) is a rare and recalcitrant, highly-malignant mesenchymal tumor in need of improved therapeutic strategies. Our laboratory pioneered the patient-derived orthotopic xenograft (PDOX) nude mouse model with the technique of surgical orthotopic implantation (SOI). We previously described the development of a PDOX model of adult pleomorphic RMS where the tumor behaved similar to the patient donor. A high-grade pleomorphic rhabdomyosarcoma from a striated muscle was previously grown orthotopically in the right biceps-femoris muscle of nude mice to establish the PDOX model. In the present study, the PDOX models were randomized into the following treatment groups when tumor volume reached 100 mm 3 : G1, control without treatment; G2, cyclophosphamide (CPA) 140 mg/kg, intraperitoneal (i.p.) injection, weekly, for 3 weeks; G3, temozolomide (TEM), 25 mg/kg, per oral (p.o.), daily, for 21 days; G4, temozolomide (TEM) 25 mg/kg, p.o., daily, for 21 days combined with irinotecan (IRN), 4 mg/kg, i.p., daily for 21 days. After 3 weeks, treatment of PDOX with TEM combined with IRN was so powerful that it resulted in tumor regression and the smallest tumor volume compared to other groups. The RMS PDOX model should be of use to design the treatment program for the patient and for drug discovery and evaluation for this recalcitrant tumor type." @default.
• W2601907443 created "2017-04-07" @default.
• W2601907443 creator A5002607014 @default.
• W2601907443 creator A5005260055 @default.
• W2601907443 creator A5010692199 @default.
• W2601907443 creator A5017915063 @default.
• W2601907443 creator A5018349469 @default.
• W2601907443 creator A5028483263 @default.
• W2601907443 creator A5032191719 @default.
• W2601907443 creator A5040819666 @default.
• W2601907443 creator A5043007782 @default.
• W2601907443 creator A5056400625 @default.
• W2601907443 creator A5060520190 @default.
• W2601907443 creator A5070052371 @default.
• W2601907443 creator A5073758146 @default.
• W2601907443 creator A5077449490 @default.
• W2601907443 creator A5081080411 @default.
• W2601907443 date "2017-03-24" @default.
• W2601907443 modified "2023-09-30" @default.
• W2601907443 title "Temozolomide combined with irinotecan caused regression in an adult pleomorphic rhabdomyosarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model" @default.
• W2601907443 cites W1239224350 @default.
• W2601907443 cites W1492549565 @default.
• W2601907443 cites W1569875761 @default.
• W2601907443 cites W1592125379 @default.
• W2601907443 cites W1805852575 @default.
• W2601907443 cites W192601499 @default.
• W2601907443 cites W1969705513 @default.
• W2601907443 cites W1975044418 @default.
• W2601907443 cites W1980325735 @default.
• W2601907443 cites W1985006583 @default.
• W2601907443 cites W1989691634 @default.
• W2601907443 cites W1997855844 @default.
• W2601907443 cites W1998139955 @default.
• W2601907443 cites W1998296205 @default.
• W2601907443 cites W2014844807 @default.
• W2601907443 cites W2021522681 @default.
• W2601907443 cites W2026104663 @default.
• W2601907443 cites W2027818468 @default.
• W2601907443 cites W2028701135 @default.
• W2601907443 cites W2028897352 @default.
• W2601907443 cites W2032117049 @default.
• W2601907443 cites W2040275378 @default.
• W2601907443 cites W2052625497 @default.
• W2601907443 cites W2103690933 @default.
• W2601907443 cites W2107307464 @default.
• W2601907443 cites W2131746764 @default.
• W2601907443 cites W2272577140 @default.
• W2601907443 cites W2306887830 @default.
• W2601907443 cites W2332572212 @default.
• W2601907443 cites W2333800042 @default.
• W2601907443 cites W2342246138 @default.
• W2601907443 cites W2408339495 @default.
• W2601907443 cites W2419037363 @default.
• W2601907443 cites W249545773 @default.
• W2601907443 cites W2516251801 @default.
• W2601907443 cites W2527335053 @default.
• W2601907443 cites W2550476383 @default.
• W2601907443 cites W2550513787 @default.
• W2601907443 cites W2574695762 @default.
• W2601907443 cites W347202097 @default.
• W2601907443 doi "https://doi.org/10.18632/oncotarget.16548" @default.
• W2601907443 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5652670" @default.
• W2601907443 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29100276" @default.
• W2601907443 hasPublicationYear "2017" @default.
• W2601907443 type Work @default.
• W2601907443 sameAs 2601907443 @default.
• W2601907443 citedByCount "31" @default.
• W2601907443 countsByYear W26019074432017 @default.
• W2601907443 countsByYear W26019074432018 @default.
• W2601907443 countsByYear W26019074432019 @default.
• W2601907443 countsByYear W26019074432020 @default.
• W2601907443 countsByYear W26019074432021 @default.
• W2601907443 crossrefType "journal-article" @default.
• W2601907443 hasAuthorship W2601907443A5002607014 @default.
• W2601907443 hasAuthorship W2601907443A5005260055 @default.
• W2601907443 hasAuthorship W2601907443A5010692199 @default.
• W2601907443 hasAuthorship W2601907443A5017915063 @default.
• W2601907443 hasAuthorship W2601907443A5018349469 @default.
• W2601907443 hasAuthorship W2601907443A5028483263 @default.
• W2601907443 hasAuthorship W2601907443A5032191719 @default.
• W2601907443 hasAuthorship W2601907443A5040819666 @default.
• W2601907443 hasAuthorship W2601907443A5043007782 @default.
• W2601907443 hasAuthorship W2601907443A5056400625 @default.
• W2601907443 hasAuthorship W2601907443A5060520190 @default.
• W2601907443 hasAuthorship W2601907443A5070052371 @default.
• W2601907443 hasAuthorship W2601907443A5073758146 @default.
• W2601907443 hasAuthorship W2601907443A5077449490 @default.
• W2601907443 hasAuthorship W2601907443A5081080411 @default.
• W2601907443 hasBestOaLocation W26019074431 @default.
• W2601907443 hasConcept C121608353 @default.
• W2601907443 hasConcept C126322002 @default.
• W2601907443 hasConcept C142724271 @default.
• W2601907443 hasConcept C143998085 @default.
• W2601907443 hasConcept C2776522094 @default.
• W2601907443 hasConcept C2776694085 @default.
• W2601907443 hasConcept C2777389519 @default.
• W2601907443 hasConcept C2778256501 @default.
• W2601907443 hasConcept C2780259306 @default.

• next